Win32 Virus Removal

Rochester NY aEUR" www.shamrockstocks.com names (OTCBB: GOVX | PowerRating) GeoVax Labs, Inc., (OTCBB: CTSO | PowerRating) Cytosorbents Corp., and (OTCBB: BFRE | PowerRating) Bluefire Ethanol Fuels, Inc. itaEUR(TM)s aEURoeLucky Picks of the Day!

To feature your publicly traded company in our alers email us at info@shamrockstocks.com.

Also, you can receive up to the minute stock alerts via our Twitter page. www.twitter.com/shamrockstocks

Visit: www.shamrockstocks.com

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccinesaEUR(TM) safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVaxaEUR(TM)s Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Earlier this year, patient enrollment began in a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit http://www.geovax.com.

News Today:

ATLANTA, Sept 27, 2010 aEUR" Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, will present the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference to be held in Atlanta from September 28 to October 1. The talk, to be given on Thursday, September 30th in a symposium titled aEURoeBlocking HIV/SIV TransmissionaEUR will report the findings of a preclinical study conducted at the Yerkes National Primate Research Center at Emory University led by Drs. Lilin Lai, Rama Amara and Robinson. The study was supported by GeoVax with funding provided through an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

The team used simian immunodeficiency virus (SIVmac)239 vaccines and a heterologous SIVsmE660 challenge in rhesus macaques to test the utility of co-expressed GM-CSF in the DNA vaccine. The inclusion of the GM-CSF in the vaccine increased protection from 25% to 71%. The protection appeared to completely block infection (versus merely controlling infection), providing what is called aEURoesterilizingaEUR immunity, a highly desirable characteristic for an AIDS vaccine. Impressively, the protection was against 12 weekly intrarectal exposures at a dose estimated to be 100 to 1000 times higher than typical human exposures during heterosexual transmission.

Dr. Robinson said, aEURoeOur results suggest that a GM-CSF-adjuvanted DNA/MVA HIV/AIDS vaccine may be able to achieve much higher levels of prevention of infection than achieved in the ground-breaking study in Thailand in which 31% of participants were protected by a vaccine.aEUR

A correlate, or marker, for the immune responses that had blocked infection, was the avidity (tightness of binding) of the vaccine-induced antibodies for the envelope glycoprotein of the challenge virus. The HIV-1 envelope glycoprotein is the aEURoekeyaEUR for HIV-1 entry into cells. aEURoeThis is the first time prevention of infection has been associated with a vaccine-induced antibody response and is an exciting result for the AIDS vaccine field where a primary goal has been to raise antibody that can block incoming virus,aEUR said Dr. Robinson.

The adjuvanted vaccine study establishes a new benchmark for protection in the preclinical SIV model, achieving a level of protection that is similar to the highly successful polio vaccine. The unadjuvanted HIV-1 form of the vaccine has proven to be both safe and immunogenic in human clinical trials and has advanced to a Phase 2a trial through the US NIH sponsored HIV Vaccine Trials Network. aEURoeHistorically, the use of GM-CSF in humans has been quite safe,aEUR said Dr. Robinson. aEURoeThus there is considerable promise for successful translation of these preclinical findings into human protection.aEUR

aEURoeWe continue to move forward with the current version of our vaccine in Phase 2 human trials and have no plans to alter that program,aEUR said Dr. Robert McNally, CEO of GeoVax. aEURoeBut the data from this study are so compelling that we are accelerating the planning to move the GM-CSF-adjuvanted vaccine into human trials as quickly as possible. Should the current version of our vaccine prove suboptimal, the adjuvanted vaccine will be a strong reserve - and at the very least, it could become the second generation of our HIV vaccine.aEUR

About AIDS Vaccine 2010

Since the first conference, organized in Paris in 2000, the AIDS Vaccine conference has become one of the most important annual events for the exchange of scientific information relating to HIV vaccine research and development. Beginning in 2007, the annual conference is organized under the aegis of the Global HIV Vaccine Enterprise and contributes to the goals of the Enterprise by providing a venue for an international exchange of information in HIV vaccine research and development, cross-fertilizing scientific areas of research, increasing coordination and communication among international groups, and monitoring progress in the field. For more information, please visit http://www.hivvaccineenterprise.org/conference/2010.

Visit: www.shamrockstocks.com

About CytoSorbents and CytoSorb(TM)

CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, often called aEURoeoverwhelming infection,aEUR with a novel blood purification device called CytoSorb(TM). Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the bodyaEUR(TM)s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called aEURoecytokine storm,aEUR that then causes multi-organ failure and often death. CytoSorb(TM) is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb(TM) cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial aEUR" a multi-center, randomized, controlled clinical trial using CytoSorb(TM) to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb(TM) in the European Union. Importantly, cytokine reduction via CytoSorb(TM) has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and other. CytoSorb(TM) is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the CompanyaEUR(TM)s website: www.cytosorbents.com

News Today:

MONMOUTH JUNCTION, NJ, Sep 27, 2010 aEUR" CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced the achievement of ISO 13485:2003 Full Quality Systems certification, a major milestone. ISO 13485 is an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the European Union (E.U.). It is a regulatory requirement of the E.U.aEUR(TM)s Medical Device Directive and an important step toward attaining European CE Mark approval.

Dr. Phillip Chan, Chief Executive Officer, stated, aEURoeWe are very pleased to have attained this key milestone. ISO 13485 certification confirms that our manufacturing and quality systems meet the same high standards required of other major US medical device companies selling into Europe. Of the possible options, Full Quality Systems certification is the most stringent and efficient route to CE Mark approval for CytoSorb(TM) and other future CytoSorbents products. When coupled with CE Mark approval, ISO 13485 certification will allow CytoSorbents to commercialize its products in the E.U. market and other countries that recognize the ISO 13485 and CE Mark standards.aEUR

Visit: www.shamrockstocks.com

About BlueFire Renewables, Inc.

BlueFire Renewables, Inc. was established to deploy a commercially ready, patented and proven Concentrated Acid Hydrolysis Technology Process for the profitable conversion of cellulosic waste materials (aEURoeGreen WasteaEUR) to renewable fuel sources, including Cellulosic Ethanol, Biodiesel, BioJet Fuel, and Drop-in Directs. BlueFire is the only cellulose-to-fuel company worldwide with demonstrated production of Biofuels from urban trash (post-sorted MSW), rice and wheat straws, wood waste and other agricultural residues.

BlueFire received an increase to its Grant totaling $88 million under the American Recovery and Reinvestment Act in December of 2009. BlueFireaEUR(TM)s biorefineries will be located near markets with high demand for ethanol and will use locally available biomass. This should dramatically reduce delivery costs and increase biofuel supplies, while providing a unique waste processing technology to help AmericaaEUR(TM)s cities better manage the increasing problem of overflowing landfills. For more information, please visit www.BFREINC.com.

If you would like to receive regular updates on BlueFire Renewables, please select this following link: http://www.b2i.us/irpass.asp?BzID=1437&to=ea&s=0.

About Cooper Marine & Timberlands:

Cooper Marine & Timberlands (CMT), a Cooper/T. Smith company headquartered in Mobile, has utilized its strengths to build one of the largest forest product systems in the South. With a self-contained cost base and through vertical integration, Cooper, Marine & Timberlands covers every dimension in the sale and production of forest products. Their chip mills, wood yards, pushboats, barges, barge fleets, and port facilities have allowed them to truly become a lowest cost operator.

Cooper/T. Smith is one of AmericaaEUR(TM)s oldest and largest maritime service related firms with operations on all three U.S. coasts encompassing thirty-eight ports, as well as foreign operations in Brazil, Canada and Mexico. The Company also maintains ownership in numerous satellite businesses, complementing the Company objectives.

Cooper/T. Smith is a progressive and innovative organization employing thousands. Its subsidiaries include warehousing, insurance, terminal operations, tugboats, push boats, barging, barge fleeting, floating terminals, and forest products. In fact, the Company impacts an astonishing array of industries throughout the country, from agriculture and energy to chemicals and construction.

News Today

IRVINE, Calif. and MOBILE, Ala., Sept 27, 2010 aEUR" BlueFire Renewables, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the worldaEUR(TM)s transportation fuel paradigm through the production of renewable fuels from non-food cellulosic wastes, announced a contract with Cooper Marine & Timberlands to provide feedstock for BlueFireaEUR(TM)s planned cellulosic ethanol facility in Fulton, MS for a period of up to 15 years.

(Logo: http://photos.prnewswire.com/prnh/20090511/BLUEFIRELOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090511/BLUEFIRELOGO)

Under the agreement, Cooper Marine & Timberlands (aEURoeCMTaEUR) will supply BlueFireaEUR(TM)s Fulton, Mississippi project with all of the feedstock required to produce approximately 19-million gallons of ethanol per year from locally sourced cellulosic materials such as wood chips, forest residual chips, pre-commercial thinnings and urban wood waste such as construction waste, storm debris, land clearing; or manufactured wood waste from furniture manufacturing.

aEURoeThis agreement is another significant step forward for BlueFire and we are excited to have CMTaEUR(TM)s participation in our Fulton Project. Coupled with our recently-announced off-take agreement with Tenaska BioFuels, LLC, the key input and output contracts required for financing are now resolved,aEUR stated Arnold Klann, CEO of BlueFire Renewables, Inc. aEURoeThis is a very exciting time for BlueFire Renewables as we complete the final steps to bringing cellulosic ethanol to fruition in the U.S. marketplace.aEUR

Under the Agreement, CMT will pursue a least-cost strategy for feedstock supply made possible by the project siteaEUR(TM)s proximity to feedstock sources and the flexibility of BlueFireaEUR(TM)s process to use a wide spectrum of cellulosic waste materials in pure or mixed forms.

Cooper Marine Timberlands (CMT), with several chip mills in operation in Mississippi and Alabama, is a member company of Cooper/T. Smith one of AmericaaEUR(TM)s oldest and largest stevedoring and maritime related firms with operations on all three U.S. coasts and foreign operations in Central and South America.

aEURoeResponsible biomass production has an important role to play in improving the state of local economies. We look forward to utilizing our extensive experience in biomass feedstock procurement and logistics in establishing a sustainable biomass feedstock supply chain for BlueFireaEUR(TM)s Fulton Project,aEUR stated Phil Willingham, Executive Vice President of Cooper Marine and Timberlands.

The Fulton, MS project will put to work MississippiaEUR(TM)s significant biomass resources to create economic development and job creation in Mississippi. It will establish the platform for developing American energy self-sufficiency from readily available local resources.

Visit: www.shamrockstocks.com

About Shamrockstocks.com

Shamrockstocks.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by Shamrockstocks. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

For additional information, please contact info@shamrockstocks.com, www.shamrockstocks.com or www.twitter.com/shamrockstocks.

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (GOVX) GOVX. (GOVX) has Short Term PowerRatings at TradingMarkets. Details on (GOVX) Short Term PowerRatings is available at This Link.

For full details on (BFRE) BFRE. (BFRE) has Short Term PowerRatings at TradingMarkets. Details on (BFRE) Short Term PowerRatings is available at This Link.

For full details on (GOVXD) GOVXD. (GOVXD) has Short Term PowerRatings at TradingMarkets. Details on (GOVXD) Short Term PowerRatings is available at This Link.

For full details on (CTSO) CTSO. (CTSO) has Short Term PowerRatings at TradingMarkets. Details on (CTSO) Short Term PowerRatings is available at This Link.